| Name | Title | Contact Details |
|---|
At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial
MedPro Services is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portage Path Behavorial Health is a Akron, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In July 2014, Genoa Healthcare and QoL meds combined to create Genoa, a QoL Healthcare Company, the nation`s leading behavioral health specialty pharmacy company. This merger brought together two pharmacy organizations with proven track records for excellent service to individuals with mental illness. Both companies had strong reputations for outstanding customer service, flexibility and delivering true value to their consumers and partners. By uniting their strengths – like best practices and expertise – the combined company was able to better serve individuals and the health organizations that care for them over the past year. Genoa has been serving the behavioral health community for over 15 years. The company now provides specialty behavioral health and long-term care pharmacy services to more than 500,000 individuals annually, operating over 285 pharmacies in 39 states and the District of Columbia and filling more than 9 million prescriptions per year. Although Genoa specializes in serving behavioral health consumers, we are a full-service pharmacy. This means we take care of all the medication needs of our consumers, including prescriptions written by psychiatrists, primary care providers, or other specialty prescribers. Genoa remains flexible to the many behavioral health and primary care delivery models across the country and developed services within our pharmacies to meet the needs of those specific models. None of our service models or pharmacies are the same. We take pride in not being a "cookie cutter" organization, and continue to seek opportunities nationwide to help behavioral health communities with their pharmacy services.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.